Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report

Introduction: Treatment options for HER2-mutant patients with non-small cell lung cancer (NSCLC) are limited. New agents, including zongertinib, a HER2-selective tyrosine kinase inhibitor (TKI), are being investigated in clinical trials. However, published clinical data on the efficacy and safety of...

Full description

Saved in:
Bibliographic Details
Main Authors: Oliver Illini, Anna Sophie Lang-Stöberl, Hannah Fabikan, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Zongertinib
BI 1810631
HER 2 mutation
HER 2 inhibitors
Non-small cell lung cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225000139
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items